Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1I01RX001449-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Enrollment difficulties
Not provided
| Name | Class |
|---|---|
| University of Florida | OTHER |
Not provided
Not provided
Not provided
The purpose of this study is to determine whether testosterone plus finasteride treatment will improve musculoskeletal health, neuromuscular function, body composition, and metabolic health in hypogonadal men who have experienced ambulatory dysfunction subsequent to incomplete spinal cord injury. The investigators hypothesize that this treatment will improve bone mineral density, enhance muscle size and muscle function, and improve body composition, without causing prostate enlargement.
Men with spinal cord injury (SCI) experience a high prevalence of hypogonadism which influences the neural, muscular, skeletal, and body composition deficits that occur after injury. It remains unknown whether testosterone administration improves bone mineral density, muscle mass and muscle function, and body composition / metabolic health in hypogonadal men who have experienced ambulatory dysfunction subsequent to incomplete spinal cord injury. In addition, it is unknown whether testosterone or the 5-alpha reduced metabolite dihydrotestosterone (an endogenous metabolite of testosterone) mediate effects in these and other tissues.
For this study hypogonadal men with motor incomplete spinal cord injury who present with ambulatory dysfunction will be randomized to receive testosterone plus the 5-alpha reductase inhibitor finasteride or a placebo treatment for 12 months. Testosterone or placebo injection will be administered weekly; finasteride or placebo will be administered daily. Participants will be assessed at study entry and at 1-6 month intervals thereafter. Assessments will include measurements such as a dual energy x-ray absorptiometry (DEXA) scan, MRI scan, and muscle performance tests. Participants will also have several safety tests, including electrocardiogram (EKG) for cardiac electrophysiology, prostate digital rectal exam and prostate ultrasound sizing for prostate health, and blood tests to assess hematocrit, liver enzymes (AST and ALT), prostate specific antigen (PSA), cholesterol, and other health markers.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| testosterone enanthate, finasteride | Experimental | Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day) |
|
| placebo treatment | Placebo Comparator | Placebo via i.m. injection (once weekly) and placebo pill orally (daily) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Testosterone Enanthate | Drug | Subjects receive testosterone (125 mg/week) by intramuscular injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change in Hip Bone Mineral Density | Percent change in total hip bone mineral density of the non-dominant limb assessed via dual-energy X-ray absorptiometry (DXA) | Baseline, 6 months, 12 months |
| Percent Changes in Muscle Cross-Sectional Area | Percent Change in thigh (knee extensors) muscle cross-sectional area of the non-dominant limb assessed via MRI | Baseline, 6 months, 12 months |
| Percent Change in Total Body Fat | Percent change in total body fat assessed via dual-energy x-ray absorptiometry (DXA) | Baseline, 6 months, 12 months |
| Absolute Change in Walking Speed | Absolute change in 10 m walking speed | Baseline, 6 months, 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change in Neuromuscular Function | Percent change in thigh (knee extensors) peak isometric torque production of the non-dominant limb assessed via dynamometry | Baseline, 6 months, 12 months |
| Percent Change in Visceral Fat |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Participants must be male
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joshua F Yarrow, PhD MS BS | North Florida/South Georgia Veterans Health System, Gainesville, FL | Principal Investigator |
| Dana M Otzel, PhD | North Florida/South Georgia Veterans Health System, Gainesville, FL | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| North Florida/South Georgia Veterans Health System, Gainesville, FL | Gainesville | Florida | 32608 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39722695 | Derived | Otzel DM, Nichols L, Conover CF, Marangi SA, Kura JR, Iannaccone DK, Clark DJ, Gregory CM, Sonntag CF, Wokhlu A, Ghayee HK, McPhaul MJ, Levy CE, Plumlee CA, Sammel RB, White KT, Yarrow JF. Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury-a randomized, double-blind, and placebo-controlled pilot study. Front Neurol. 2024 Dec 11;15:1479264. doi: 10.3389/fneur.2024.1479264. eCollection 2024. |
Not provided
Not provided
Data will be shared according to the requirements described by the Department of Veterans Affairs, Office of Research & Development.
Not provided
Data will be shared according to the requirements described by the Department of Veterans Affairs, Office of Research & Development.
Data will be shared according to the requirements described by the Department of Veterans Affairs, Office of Research & Development.
Not provided
Enrolled participants were evaluated at an in-person screening visit to determine if they qualify. Those that did not qualify were excluded from the study before randomization. Of 33 enrolled participants, 12 met inclusion criteria and were randomized to treatment / placebo groups.
Participants were recruited based on physician referrals at 2 VA medical centers and via community-based advertisements between January 2017 and March 2021 and pre-screened via phone to determine criteria to enroll. Those meeting criteria to enroll were screened for potential eligibility, with the first participant enrolled on April 27, 2017 and the last participant enrolled on December 4, 2020.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Testosterone Enanthate, Finasteride | Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day) Testosterone Enanthate: Subjects receive testosterone (125 mg/week) by intramuscular injection Finasteride: Subjects receive finasteride (5 mg/day) orally |
| FG001 |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 3, 2022 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Finasteride | Drug | Subjects receive finasteride (5 mg/day) orally |
|
|
| Placebo injection | Drug | Subjects receive placebo (weekly) by intramuscular injection |
|
|
| Placebo pill | Drug | Subjects receive placebo pill (daily) orally |
|
|
Percent change in visceral (android) fat mass assessed via dual-energy x-ray absorptiometry (DXA)
| Baseline, 6 months, 12 months |
| James A. Haley Veterans' Hospital, Tampa, FL |
| Tampa |
| Florida |
| 33612 |
| United States |
| Placebo Treatment |
Placebo via i.m. injection (once weekly) and placebo pill orally (daily) Placebo injection: Subjects receive placebo (weekly) by intramuscular injection Placebo pill: Subjects receive placebo pill (daily) orally |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Testosterone Enanthate, Finasteride | Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day) Testosterone Enanthate: Subjects receive testosterone (125 mg/week) by intramuscular injection Finasteride: Subjects receive finasteride (5 mg/day) orally |
| BG001 | Placebo Treatment | Placebo via i.m. injection (once weekly) and placebo pill orally (daily) Placebo injection: Subjects receive placebo (weekly) by intramuscular injection Placebo pill: Subjects receive placebo pill (daily) orally |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
| ||||||||||||||||
| Hip bone mineral density | non-dominant leg total hip bone mineral density, assessed via DXA | N=1 participant in the was not analyzed in the testosterone enanthate, finasteride group due to bilateral hip joint replacement present at baseline. | Mean | Standard Deviation | g/cm^2 |
| |||||||||||||
| Thigh muscle cross-sectional area | non-dominant leg knee extensors muscle cross-sectional area, assessed via MRI | Mean | Standard Deviation | cm^2 |
| ||||||||||||||
| Total body fat | assessed via DXA | Only N=6 analyzed in the testosterone enanthate, finasteride group because data was corrupted at baseline on N=1 participant. | Mean | Standard Deviation | kg |
| |||||||||||||
| Walking speed | assessed via 10m walking test | Mean | Standard Deviation | m/s |
| ||||||||||||||
| Neuromuscular function | non-dominant leg, thigh (knee extensors) peak isometric torque production via dynamometry | Mean | Standard Deviation | N/m |
| ||||||||||||||
| Visceral fat | Android fat assessed via DXA | Only N=6 analyzed in the testosterone enanthate, finasteride group because data was corrupted at baseline on N=1 participant. | Mean | Standard Deviation | kg |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent Change in Hip Bone Mineral Density | Percent change in total hip bone mineral density of the non-dominant limb assessed via dual-energy X-ray absorptiometry (DXA) | Only 5 participants in the testosterone enanthate group were evaluated because 1 of 6 with baseline values had withdrawn prior to 6 months. At 12 months: 2 participants in the placebo group and 2 additional participants in the testosterone enanthate group had withdrawn from the study and data from 1 participant in the testosterone enanthate group could not be analyzed due to imaging artefact. | Posted | Mean | Standard Deviation | percent change | Baseline, 6 months, 12 months |
|
|
| ||||||||||||||||||||||||||||
| Primary | Percent Changes in Muscle Cross-Sectional Area | Percent Change in thigh (knee extensors) muscle cross-sectional area of the non-dominant limb assessed via MRI | Only 5 participants in the testosterone enanthate group were evaluated because 2 of 7 with baseline values had withdrawn prior to 6 months. Only 4 participants in the placebo group were evaluated because 1 of 5 with baseline values did not have a follow-up MRI. At 12 months: 1 participant in the placebo group and 2 additional participants in the testosterone enanthate group had withdrawn from the study. | Posted | Mean | Standard Deviation | percent change | Baseline, 6 months, 12 months |
|
| |||||||||||||||||||||||||||||
| Primary | Percent Change in Total Body Fat | Percent change in total body fat assessed via dual-energy x-ray absorptiometry (DXA) | Only 4 participants in the testosterone enanthate group were evaluated because 2 of 6 with baseline values had withdrawn prior to 6 months. At 12 months: 2 participants in the placebo group had withdrawn from the study and 2 additional participants in the testosterone enanthate group had withdrawn from the study. | Posted | Mean | Standard Deviation | percent change | Baseline, 6 months, 12 months |
|
| |||||||||||||||||||||||||||||
| Primary | Absolute Change in Walking Speed | Absolute change in 10 m walking speed | Only 5 participants in the testosterone enanthate group were evaluated because 2 of 7 with baseline values had withdrawn prior to 6 months. At 12 months: 2 participants had withdrawn from the placebo group and an additional 2 participants had withdrawn from the testosterone enanthate group. | Posted | Mean | Standard Deviation | meters/second (m/s) change | Baseline, 6 months, 12 months |
|
| |||||||||||||||||||||||||||||
| Secondary | Percent Change in Neuromuscular Function | Percent change in thigh (knee extensors) peak isometric torque production of the non-dominant limb assessed via dynamometry | Only 5 participants in the testosterone enanthate group were evaluated because 2 of 7 with baseline values had withdrawn prior to 6 months. At 6 months: 1 participant in the placebo group and 1 participant in the testosterone enanthate group did not perform testing. At 12 months: 2 participants in the placebo group had withdrawn from the study and 2 additional participant in the testosterone enanthate group had withdrawn from the study. | Posted | Mean | Standard Deviation | percent change | Baseline, 6 months, 12 months |
| ||||||||||||||||||||||||||||||
| Secondary | Percent Change in Visceral Fat | Percent change in visceral (android) fat mass assessed via dual-energy x-ray absorptiometry (DXA) | Only 4 participants in the testosterone enanthate group were evaluated because 2 of 6 with baseline values had withdrawn prior to 6 months. At 12 months: 2 participants in the placebo group had withdrawn from the study and 2 additional participants in the testosterone enanthate group had withdrawn from the study. | Posted | Mean | Standard Deviation | percent change | Baseline, 6 months, 12 months |
|
|
12 months
Data on adverse events were assessed at regular study visits and via weekly phone assessments with all study participants.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Testosterone Enanthate, Finasteride | Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day) Testosterone Enanthate: Subjects receive testosterone (125 mg/week) by intramuscular injection Finasteride: Subjects receive finasteride (5 mg/day) orally | 0 | 7 | 1 | 7 | 7 | 7 |
| EG001 | Placebo Treatment | Placebo via i.m. injection (once weekly) and placebo pill orally (daily) Placebo injection: Subjects receive placebo (weekly) by intramuscular injection Placebo pill: Subjects receive placebo pill (daily) orally | 0 | 5 | 0 | 5 | 5 | 5 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hospitalization | Infections and infestations | Systematic Assessment | Hospitalization due to severe acute respiratory syndrome (SARS)-CoV-2 (COVID-19) infection |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| aldolase, high | General disorders | Systematic Assessment | above standard reference range (<=8.1 U/L); test performed on only 1 participant at request of study physician |
| |
| anion gap, high | General disorders | Systematic Assessment | above standard reference range (5-15 mmol/L) |
| |
| alanine aminotransferase (ALT), high | Investigations | Systematic Assessment | above standard reference range (0-40 U/L) |
| |
| aspartate aminotransferase (AST), high | Investigations | Systematic Assessment | above standard reference range (0-45 U/L) |
| |
| albumin, high | General disorders | Systematic Assessment | above standard reference range (3.5-5.0 g/dL) |
| |
| alkaline phosphatase, high | General disorders | Systematic Assessment | above standard reference range (0-125 U/L) |
| |
| calcium, high | Investigations | Systematic Assessment | above standard reference range (8.4-10.5 mg/dL) |
| |
| total cholesterol, high | Investigations | Systematic Assessment | above standard reference range (0-199 mg/dL); all participants in testosterone enanthate, finasteride group exhibited cholesterol values above standard reference range at baseline (before treatment initiation) |
| |
| chloride, low | General disorders | Systematic Assessment | below standard reference range (98-108 mmol/L) |
| |
| CO2, low | General disorders | Systematic Assessment | below standard reference range (23-32 mmol/L) |
| |
| creatine phosphokinase (CPK), high | General disorders | Systematic Assessment | above standard reference range (5-180 U/L); test performed on only 1 participant at request of study physician |
| |
| creatinine, high | General disorders | Systematic Assessment | above standard reference range (0.5-1.2 mg/dL) |
| |
| C-reactive protein (CRP), high | General disorders | Systematic Assessment | above standard reference range (<0.1-0.4 mg/dL); 3 of 6 testosterone enanthate, finasteride participants and 1 of 3 placebo participants with elevated CRP exhibited values above standard reference range at baseline (before treatment initiation) |
| |
| dihydrotestosterone, high | Investigations | Systematic Assessment | above standard reference range (16-79 ng/dL) |
| |
| dihydrotestosterone, low | Investigations | Systematic Assessment | below standard reference range (16-79 ng/dL) |
| |
| dysarthria | Nervous system disorders | Systematic Assessment |
| ||
| edema | Investigations | Systematic Assessment | present in upper and lower extremities |
| |
| impaired ejaculation | Reproductive system and breast disorders | Systematic Assessment | patient reported outcome |
| |
| estradiol, high | Investigations | Systematic Assessment | above standard reference range (<=29 pg/mL) |
| |
| eosinophils, high | General disorders | Systematic Assessment | above standard reference range (0-3%) |
| |
| erythropoietin, high | General disorders | Systematic Assessment | above standard reference range (2.6-18.5 mIU/mL) |
| |
| eye infection | Eye disorders | Systematic Assessment |
| ||
| depression | Psychiatric disorders | Systematic Assessment | transient depression, self reported |
| |
| falls | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| glucose, high | Investigations | Systematic Assessment | above standard reference range (65-99 mg/dL); 7 of 7 participants in testosterone enanthate, finasteride group and 3 of 5 participants in placebo group exhibited glucose values above standard reference range at baseline (before treatment initiation) |
| |
| granulocytes, high | General disorders | Systematic Assessment | above standard reference range (54-65%) |
| |
| granulocytes, low | General disorders | Systematic Assessment | below standard reference range (54-65%) |
| |
| HDL cholesterol, low | Investigations | Systematic Assessment | below standard reference range (>=40 mg/dL); 3 of 5 participants in testosterone enanthate, finasteride group and 2 of 2 participants in placebo group with low HDL exhibited values below reference range at baseline (before treatment initiation) |
| |
| hematocrit, high | Investigations | Systematic Assessment | above standard reference range (41-52%) |
| |
| hematocrit, low | Investigations | Systematic Assessment | below standard reference range (41-52%) |
| |
| hemoglobin, high | Investigations | Systematic Assessment | above standard reference range (13.9-18 g/dL) |
| |
| hemoglobin, low | Investigations | Systematic Assessment | below standard reference range (13.9-18 g/dL) |
| |
| insulin, high | Investigations | Systematic Assessment | above standard reference range (<=19.6 uIU/mL) |
| |
| potassium, high | General disorders | Systematic Assessment | above standard reference range (3.5-5.0 mmol/L) |
| |
| potassium, low | General disorders | Systematic Assessment | below standard reference range (3.5-5.0 mmol/L) |
| |
| LDL cholesterol, high | Investigations | Systematic Assessment | above standard reference range (<=129 mg/dL); 3 of 3 participants in testosterone enanthate, finasteride group with high LDL cholesterol exhibited values above standard reference range at baseline (before treatment initiation) |
| |
| lymphocytes, high | General disorders | Systematic Assessment | above standard reference range (25-33%) |
| |
| lymphocytes, low | General disorders | Systematic Assessment | below standard reference range (25-33%) |
| |
| mean corpuscular hemoglobin, low | General disorders | Systematic Assessment | below standard reference range (27-33.3 pg) |
| |
| mean corpuscular hemoglobin concentration, low | General disorders | Systematic Assessment | below standard reference range (31.8-37.1 g/dL) |
| |
| mean corpuscle volume, high | General disorders | Systematic Assessment | above standard reference range (80-98 um^3) |
| |
| mean corpuscle volume, low | General disorders | Systematic Assessment | below standard reference range (80-98 um^3) |
| |
| monocytes, high | General disorders | Systematic Assessment | above standard reference range (3-7%); 6 of 7 participants in testosterone enanthate, finasteride group and 3 of 5 participants in placebo group exhibited monocyte values above standard reference range at baseline (before treatment initiation) |
| |
| mean platelet volume, high | General disorders | Systematic Assessment | above standard reference range (7.4-10.5 um^3) |
| |
| myelocytes, high | General disorders | Systematic Assessment | above standard reference range (0) |
| |
| musculoskeletal pain | Musculoskeletal and connective tissue disorders | Systematic Assessment | self reported |
| |
| otitis media | Ear and labyrinth disorders | Systematic Assessment | ear infection |
| |
| paresthesia | Nervous system disorders | Systematic Assessment |
| ||
| penile shrinkage | Reproductive system and breast disorders | Systematic Assessment | self reported |
| |
| total protein, high | General disorders | Systematic Assessment | above standard reference range (6.0-8.2 g/dL) |
| |
| prostate-specific antigen (PSA), high | Investigations | Systematic Assessment | above standard reference range (0-4 ng/mL or increase >1.4 ng/mL vs baseline); 1 of 2 participants in testosterone enanthate, finasteride group with high PSA tested positive for urinary tract infection 2 different times with PSA renormalizing |
| |
| prostate induration | Investigations | Systematic Assessment | noted on digital rectal exam of prostate |
| |
| red blood cell count, low | General disorders | Systematic Assessment | below standard reference range (4.44-6.1 M/cmm) |
| |
| red blood cell distribution width, high | General disorders | Systematic Assessment | above standard reference range (39.0-52.2 fL) |
| |
| red blood cell distribution width, low | General disorders | Systematic Assessment | below standard reference range (39.0-52.2 fL) |
| |
| segmented neurtrophils, low | General disorders | Systematic Assessment | below standard reference range (54-65%) |
| |
| sex-hormone binding globulin (SHBG), high | General disorders | Systematic Assessment | above standard reference range (10-50 nmol/L) |
| |
| sex-hormone binding globulin (SHBG), low | General disorders | Systematic Assessment | below standard reference range (10-50 nmol/L) |
| |
| sodium, high | General disorders | Systematic Assessment | above standard reference range (135-145 mmol/L) |
| |
| testicular size reduced | Reproductive system and breast disorders | Systematic Assessment | self reported outcome |
| |
| testosterone, high | Investigations | Systematic Assessment | above standard reference range (193-836 ng/dL) |
| |
| testosterone, low | Investigations | Systematic Assessment | below standard reference range (193-836 ng/dL) |
| |
| triglycerides, high | Investigations | Systematic Assessment | above standard reference range (0-149 mg/dL) |
| |
| urea nitrogen, high | General disorders | Systematic Assessment | above standard reference range (9-20 mg/dL) |
| |
| urea nitrogen, low | General disorders | Systematic Assessment | below standard reference range (9-20 mg/dL) |
| |
| urobilinogen, high | General disorders | Systematic Assessment | above standard reference range (0.00-1.99 mg/dL) |
| |
| urinary tract infection | Renal and urinary disorders | Systematic Assessment | As a result of self-catheterization |
| |
| white blood cell count, high | General disorders | Systematic Assessment | above standard reference range (4.6-10.8 k/cmm) |
| |
| white blood cell count, low | General disorders | Systematic Assessment | below standard reference range (4.6-10.8 k/cmm) |
|
This trial was terminated early due to enrollment and retention difficulties that persisted during the severe acute respiratory syndrome (SARS)-Cov19 pandemic. This resulted in a smaller number of subjects being enrolled and undergoing testing than was originally planned in our a priori analysis.
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Joshua Yarrow, MS, PhD | North Florida/South Georgia Veterans Health System | (352) 548-6477 | Joshua.Yarrow@va.gov |
| Aug 1, 2023 |
| Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Oct 30, 2018 | May 10, 2023 | ICF_001.pdf |
| ID | Term |
|---|---|
| D013119 | Spinal Cord Injuries |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D013118 | Spinal Cord Diseases |
| D006058 | Gonadal Disorders |
| D004700 | Endocrine System Diseases |
| D007006 | Hypogonadism |
| D005832 | Genital Diseases, Male |
| D001862 | Bone Resorption |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| C004648 | testosterone enanthate |
| D018120 | Finasteride |
| D012715 | Sesame Oil |
| ID | Term |
|---|---|
| D000736 | Androstenes |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D001378 | Azasteroids |
| D013260 | Steroids, Heterocyclic |
| D004042 | Dietary Fats, Unsaturated |
| D004041 | Dietary Fats |
| D005223 | Fats |
| D008055 | Lipids |
| D005224 | Fats, Unsaturated |
| D010938 | Plant Oils |
| D009821 | Oils |
| D028321 | Plant Preparations |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
Not provided
Not provided
|
|
|
|
|
|
|
|
|
|
| Change at 12 months |
|
|
| Counts |
|---|
| Participants |
|
|
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
|